KRAS and cancer: As already mentioned, oncogene mutations, such as in Kras or TP53, or novel translocation-based proteins, such as the original bcr/abl from the Chr9/22 translocation commonly found in CML (Chronic Myelogenous Leukaemia), and the subsequently discovered similar translocations in some prostate, lung and other cancers, have proved difficult to develop as CAR T or TCB targets.